

Protein Drugs: Market Research Report

<https://marketpublishers.com/r/PFC78CFF7ACEN.html>

Date: August 2010

Pages: 524

Price: US\$ 3,950.00 (Single User License)

ID: PFC78CFF7ACEN

Abstracts

This report analyzes the Global market for Protein Drugs in US\$ Million by the following Drug Classes - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Others (Including Peptide Antibiotics and Enzymes).

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Inc., Alexion Pharmaceuticals, Inc., Amgen, Inc., Biogen Idec, Bristol-Myers Squibb Company, Medarex, Inc., Crucell N.V., Dendreon Corporation, Eli Lilly and Company, Emergent BioSolutions, Inc., Genentech, Inc., Johnson & Johnson, Centocor Ortho Biotech, Inc., MedImmune, Inc., Merck Serono S.A., Schering-Plough Corporation, UCB Group, Unigene Laboratories, Inc., and Vaccinogen, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

A Prelude
Protein Drugs Are the Best Sellers
Key Statistics:

Table 1. World Market for Biopharmaceuticals (2009): Top 10 Brands Ranked by Dollar Sales (In US\$ Billion) (includes corresponding Graph/Chart)

Table 2. World Market for Biopharmaceuticals (2007 & 2008): Top 15 Brands Ranked by Dollar Sales (In US\$ Billion)

Competitive Scenario
Intensifying Consolidation Activity
Impact of Recession: A Review
Impact of Recession on Drug Sales
Impact of Recession on R&D Activities
Not Recession, But Generic Competition Will Cause Sales Erosion
Patent Expiration
Impending Patent Expiry For Key Protein Drugs
Patent Expirations For Key Protein and Peptide Drugs in the Recent Past
Follow-on Biologics: An Opportunity in Adverse Conditions
Legal and Scientific Viability of Follow-on Protein Drugs
MAb: A Market Better Protected from Generic Competition
Approved Monoclonal Antibodies in the Market
Unmet Medical Needs in Emerging Markets Provides Fertile Environment

Key Market Trends & Issues: A Review

Continuous Fight Against Diseases: A Key Propeller for Growth

Population Aging Makes Rise Of Protein Drugs Inevitable

Ability to Address Wide Gamut of Diseases is Key to Success

Combination Biologics Can Offer New Treatment Possibilities

Shift Towards Humanized and Fully Human Antibodies

Biotechnology Gives a New Direction

Innovative Drug Delivery Methods: The Need of the Hour

Companies Seek Partnerships and Collaborations to Sustain Profit Margins

Increasing Demand for Protein A in Mab Manufacturing

Rising Number of MAbs Under Clinical Trials

Major Protein Drugs in Pipeline As of 2009

Untapped Pharmacological Potential of GPCRs Ignites Interest

Increased Reliance On Contract Manufacturing

Reimbursement & Price Sensitivity Are Key Challenges

Manufacturing Bottleneck

High Costs Impede Penetration

A Special Focus On Key Regional Markets

United States

Market Overview

Biologics: A Review

Biologics: A Costly Proposition

Recombinant Proteins To Continue Their Significance as Key Biologic Products

Recombinant Blood-Related Agents to Continue Their Market Growth

Early Generic Competition Will Unsettle Revenues for Key Protein Drugs

Key Statistics:

Table 3. US Market for Protein Therapeutics (2010): Percentage Share Breakdown of Dollar Sales for Key Therapy Area (includes corresponding Graph/Chart)

China

Market Overview

China to Emerge As Biosimilar Major

Lack of Regulatory Framework

India

Market Overview

Indian Pharma Companies Gear Up to Grab a Big Slice of Global Follow-On Biologics Market

Openness in US Market Will Provide Opportunities

2.PRODUCT OVERVIEW

An Introduction

Structural Information

Classification of Proteins

Sources of Protein Drugs

Types of Protein-Based Drugs

Cytokines

Clotting factors

Hormones

Monoclonal Antibodies (Mabs)

Vaccines

Different Types of Protein Drugs

Applications

Significance of Biotechnology in Protein-Based Drugs

Hybridoma Cell Technology

Recombinant DNA Technology

Production of Protein Drugs through Transgenic Animals

Disadvantages of Protein-based Drugs

Immunogenicity of Protein-Based Drugs

3.PRODUCT INTRODUCTIONS/LAUNCHES

Millipore Launches Magna RIPTM RNA-binding ProteinImmunoprecipitation Kit

Millipore Unveils AllostericProfilerTM Service

Caliper Life Sciences Introduces Two Products to Expand LabChip GX Product Range

BioDtech Introduces EndoPrep

Amgen Introduces Vectibix

Trevigen Introduces Mouse Monoclonal Antibody

UCB Receives FDA Approval for Cimzia®

MD Biosciences Launches Keratocan and Lumican Monoclonal Antibodies

PhyNexus Introduces PhyTip® ProPlus™ Columns

4.RECENT INDUSTRY ACTIVITY

Novartis Vaccines Receives EC Approval for Menveo®

Lonza Takes Over Algonomics

Daicel Chemical Takes Over ChromTech
Roche Licenses ProTek Stabilisation Technology of Aegis Therapeutics
Lonza to Manufacture Arzerra
Sanofi Pasteur Receives FDA Approval for Fluzone® High-Dose Vaccine
Maxygen and Astellas Complete Joint Venture Transaction
Sanofi Pasteur's Panenza® and Humenza® Vaccines Elicit Strong Immune Response
Amgen Collaborates with GSK
Nabi Biopharmaceuticals Inks Licensing Agreement with GSK
Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance
OPKO Health and Academia Sinica Ink Exclusive License Agreement
Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact
Roche and Covagen Enter into Collaboration
Lonza to Manufacture Biologics for LFB and Medarex
Protgen Establishes Protein Drug Innovation Center in Beijing
National Cheng Kung University Inks MoU with ScinoPharm Taiwan
Novo Nordisk and ZymoGenetics Signs Licensing Agreement
Lipoxen Signs Collaboration Agreement with Pharmasynthez
Debiopharm Group Inks License Agreement with Curis
Bristol-Myers Squibb Acquires Medarex
Sanofi Pasteur Signs Licensing Agreement with Syntiron
Sanofi Pasteur Inks Strategic Agreement with ShanH
Access Pharmaceuticals Acquires Somanta Pharmaceuticals
IMUC Completes Molecular Antibody Technology Acquisition
Callisto Merger Corporation Merges with Celldex Therapeutics
Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
Eusa Sells Antibody Research Business
Dyax and Sanofi-Aventis Sign Agreements
HGS Enters into Antibody Collaboration Agreement with Xencor
Wyeth Pharmaceuticals and Biovitrum Extend ReFacto Supply Agreement
Caprotec Bioanalytics and Merck Ink Collaboration Agreement
Biomonitor Snaps Up Neutekbio
GE Healthcare Takes Over MicroCal
Arana Therapeutics Enters into Collaboration with Greenovation Biotech
Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen
Sanofi Pasteur Holding Purchases Acambis
GlaxoSmithKline Enters into Strategic Alliance with Archemix
Talecris Biotherapeutics Inks License Agreement with Crucell
Polyphor Signs Exclusive Licensing Agreement with Allergan
Morphotek® Enters into Partnership with Pivotal BioSciences

PharmAthene Snaps Up Biodefence Vaccines Business of Avercia Biologics
Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement
MacroGenics Purchases Raven Biotechnologies

5.FOCUS ON SELECT PLAYERS

Abbott Laboratories, Inc. (US)
Alexion Pharmaceuticals, Inc. (US)
Amgen, Inc. (US)
Biogen Idec (US)
Bristol-Myers Squibb Company (US)
Medarex, Inc. (US)
Crucell N.V. (The Netherlands)
Dendreon Corporation (US)
Eli Lilly and Company (US)
Emergent BioSolutions, Inc. (US)
Genentech, Inc. (US)
Johnson & Johnson (US)
Centocor Ortho Biotech, Inc. (US)
MedImmune, Inc. (US)
Merck Serono S.A. (Switzerland)
Schering-Plough Corporation (US)
UCB Group (Belgium)
Unigene Laboratories, Inc. (US)
Vaccinogen, Inc. (US)

6.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Protein Drugs by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5. World 10-Year Perspective for Protein Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009, and 2015

Table 6. World Recent Past, Current and Future Analysis for Protein Drugs by Drug

Type – Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs Independently Analyzed with Annual Revenue Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 7. World 10-Year Perspective for Protein Drugs by Drug Type – Percentage Breakdown of Dollar Sales for Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 56 (including Divisions/Subsidiaries - 58)

Region/CountryPlayers

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Rest of Europe

Asia-Pacific (Excluding Japan)

I would like to order

Product name: Protein Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/PFC78CFF7ACEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFC78CFF7ACEN.html>